Cell BioEngines develops off‑the‑shelf allogeneic cell therapies using its STEM‑Space™ platform, which chemically reprograms HLA‑homozygous cord‑blood stem cells to create transgene‑free “super donor” cells that are naturally HLA‑matched to broad patient populations. By leveraging a population‑aligned biobank and scalable manufacturing, the company aims to deliver curative cell‑based drugs for oncology, hematology and regenerative medicine with reduced immune rejection risk and lower development costs.
Funding
$33.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cell therapies are largely autologous or heavily engineered allogeneic products, requiring complex manufacturing, high costs, and individualized logistics, which limit patient access and slow development across multiple disease areas.
Solution
Cell BioEngines develops off‑the‑shelf allogeneic cell therapies by chemically reprogramming clinical‑grade HLA‑homozygous cord‑blood stem cells without transgenes. Their STEM‑Space™ platform creates “super donor” stem cells, immune cells, and iPSC‑derived products that are naturally HLA‑matched to broad patient populations, reducing immune rejection risk. A population‑aligned biobank of HLA‑homozygous donors enables scalable, cost‑effective manufacturing and rapid product diversification across oncology, hematology, and regenerative medicine. The company advances candidates both internally and through strategic partnerships, aiming to deliver multiple curative cell‑based drugs with lower translational costs and shorter development timelines.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking allogeneic cell‑based therapeutics for oncology, hematologic disorders, and regenerative medicine, as well as clinical partners requiring off‑the‑shelf cell products for patient treatment.
Features
- Chemical reprogramming of HLA‑homozygous cord‑blood stem cells using small molecules, avoiding viral transgenes
- Transgene‑free, naturally HLA‑matched “super donor” cells that minimize immune rejection
- Scalable manufacturing pipeline compatible with large‑volume production
- Population‑guided biobank strategy to maximize patient coverage across diverse ethnic groups
- Platform generates multiple cell formats: HAPLO‑HSCs, HAPLO‑IMX immune cells, and HAPLO‑iPS derived therapeutics
- Flexible development model supporting both internal programs and out‑licensing partnerships